Elan (ELN -3.1%) slips on a downgrade to Neutral on valuation at UBS, noting that Bapineuzumab's...


Elan (ELN -3.1%) slips on a downgrade to Neutral on valuation at UBS, noting that Bapineuzumab's economic potential may be lower than expected.
Comments (2)
  • RBTober
    , contributor
    Comments (4) | Send Message
     
    If the drug helps even a little, it will be a block buster. Look at the sales of Aricept and Namenda which have extremely limited + impact for more than 6 months on the disease progression.
    Robert B. Tober, M.D.
    31 May 2012, 11:57 AM Reply Like
  • RBTober
    , contributor
    Comments (4) | Send Message
     
    Practicing physician in Wound Healing and Geriatrics
    31 May 2012, 11:57 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs